I N T H I S I S S U E O F
HEPATOLOGY
Volume 65 Number 6 June 2017
Hepatology Highlights
1783 Jean-Franc¸ois Dufour
Master’s Perspective
1785 Coming of Age and Building of Bridges . . . Reflections on the Past, Present, and, Hesitatingly, Future
Irwin M. Arias
Editorials
1789 Hepatitis C Treatment Threshold in Patients With Decompensated Liver Disease
Duminda Suraweera and Sammy Saab
(See Article on Page 1810) 1792 Beyond Sensing: Retinoic Acid Inducible
Gene-I (RIG-I) Continues to Expand Its Antiviral Effector Functions
Amy E.L. Stone and Michael J. Gale Jr.
(See Article on Page 1823) 1796 Expanding the Armamentarium for
Neutrophil-Mediated Angiogenesis
Brian E. Hsu and Peter M. Siegel
(See Article on Page 1920) 1799 Assessment of Systolic Function in the
Evaluation of Patients With Cirrhosis
Søren Møller and Jens D. Hove
(See Article on Page 2019)
Original Articles
R A P I D C O M M U N I C A T I O N
1803 *Sofosbuvir-Velpatasvir-Voxilaprevir With or Without Ribavirin in Direct-Acting
Antiviral–Experienced Patients With Genotype 1 Hepatitis C Virus
Eric Lawitz, Fred Poordad, Jennifer Wells, Robert H. Hyland, Yin Yang,
Hadas Dvory-Sobol, Luisa M. Stamm, Diana M. Brainard, John G. McHutchison, Carmen Landaverde, and Julio Gutierrez
V I R A L H E P A T I T I S
1810 *Treatment of Hepatitis C Virus Infection in Patients With Cirrhosis and Predictive Value of Model for End-Stage Liver Disease: Analysis of Data From the Hepa-C Registry
Carlos Fernandez Carrillo, Sabela Lens, Elba Llop, Juan Manuel Pascasio, Javier Crespo, Juan Arenas, Inmaculada Fernandez,
Carme Baliellas, Jose Antonio Carrion,
Manuel de la Mata, Maria Buti, Lluıs Castells, Agustın Albillos, Manuel Romero, Juan Turnes, Clara Pons, Jose Marıa Moreno-Planas, Jose Javier Moreno-Palomares,
Conrado Fernandez-Rodriguez,
Javier Garcıa-Samaniego, Martın Prieto, Miguel Fernandez Bermejo, Javier Salmeron, Ester Badia, Magdalena Salcedo,
Jose Ignacio Herrero, Rafael Granados, Michel Ble, Zoe Mari~no, and Jose Luis Calleja
(See Editorial on Page 1789) 1823 RIG-I Is a Key Antiviral Interferon-Stimulated
Gene Against Hepatitis E Virus Regardless of Interferon Production
Lei Xu, Wenshi Wang, Yunlong Li, Xinying Zhou, Yuebang Yin, Yijin Wang, Robert A. de Man, Luc J.W. van der Laan, Fen Huang, Nassim Kamar,
Maikel P. Peppelenbosch, and Qiuwei Pan
(See Editorial on Page 1792)
*Human Study
>
Cover Figure: Tagged mast cells (MCs) injected via tail vein into KitW-sh(MC-deficient) mice (top left) infiltrate the liver, (top right) alter the vascular bed, and (bottom left) increase hepatic fibrosis. (Bottom right) Schematic diagram of the effects of MC injection into MC-deficient mice. See article on page 1991.A
1840 *The Membrane-Bound O-Acyltransferase Domain-Containing 7 Variant rs641738 Increases Inflammation and Fibrosis in Chronic Hepatitis B
Khaled Thabet, Henry Lik Yuen Chan, Salvatore Petta, Alessandra Mangia, Thomas Berg, Andre Boonstra,
Willem P. Brouwer, Maria Lorena Abate, Vincent Wai-Sun Wong, Maiiada Nazmy, Janett Fischer, Christopher Liddle, Jacob George, and Mohammed Eslam
1851 *Apolipoprotein(a) Inhibits Hepatitis C Virus Entry Through Interaction With Infectious Particles
Catarina Oliveira, Carole Fournier, Veronique Descamps, Virginie Morel, Corey A. Scipione, Rocco Romagnuolo, Marlys L. Koschinsky, Agne`s Boullier, Paulo Marcelo, Jean-Marc Domon, Etienne Brochot, Gilles Duverlie, Catherine Francois, Sandrine Castelain, and Francois Helle
S T E A T O H E P A T I T I S / M E T A B O L I C L I V E R D I SE A S E
1865 *Activation of the c-Jun N-Terminal Kinase Pathway Aggravates Proteotoxicity of Hepatic Mutant Z Alpha1-Antitrypsin
Nunzia Pastore, Sergio Attanasio, Barbara Granese, Raffaele Castello, Jeffrey Teckman, Andrew A. Wilson, Andrea Ballabio, and Nicola Brunetti-Pierri
1875 *The PNPLA3 I148M Variant Modulates the Fibrogenic Phenotype of Human Hepatic Stellate Cells
Francesca Virginia Bruschi, Thierry Claudel, Matteo Tardelli, Alessandra Caligiuri, Thomas M. Stulnig, Fabio Marra, and Michael Trauner
1891 *Dual-Photon Microscopy-Based Quantitation of Fibrosis-Related Parameters (q-FP) to Model Disease Progression in Steatohepatitis
Yan Wang, Robert Vincent, Jinlian Yang, Amon Asgharpour, Xieer Liang,
Michael O. Idowu, Melissa J. Contos, Kalyani Daitya, Mohammed S. Siddiqui, Faridoddin Mirshahi, and Arun J. Sanyal
1904 *The Histone Methyltransferase Suv39h2 Contributes to Nonalcoholic Steatohepatitis in Mice
Zhiwen Fan, Luyang Li, Min Li, Xinjian Zhang, Chenzhi Hao, Liming Yu, Sheng Zeng, Huihui Xu, Mingming Fang, Aiguo Shen, Thomas Jenuwein, and Yong Xu
H E P A T O B I L I A R Y M A L IG N A N C I E S
1920 Neutrophils Promote Hepatic Metastasis Growth Through Fibroblast Growth Factor 2–Dependent Angiogenesis in Mice
Alex N. Gordon-Weeks, Su Y. Lim, Arseniy E. Yuzhalin, Keaton Jones,
Bostjan Markelc, K. Jin Kim, Jon N. Buzzelli, Emmanouil Fokas, Yunhong Cao, Sean Smart, and Ruth Muschel
(See Editorial on Page 1796)
1936 Inhibition of the Sterol Regulatory
Element-Binding Protein Pathway Suppresses Hepatocellular Carcinoma By Repressing Inflammation in Mice
Na Li, Zhang-Sen Zhou, Yang Shen, Jie Xu, Hong-Hua Miao, Ying Xiong, Feng Xu, Bo-Liang Li, Jie Luo, and Bao-Liang Song
1948 *Polymeric Immunoglobulin Receptor Promotes Tumor Growth in Hepatocellular Carcinoma
Xihua Yue, Jing Ai, Yang Xu, Yi Chen, Min Huang, Xinying Yang, Bo Hu,
Haotian Zhang, Changxi He, Xinrong Yang, Weiguo Tang, Xia Peng, Liwei Dong, Hongyang Wang, Jia Fan, Jian Ding, and Meiyu Geng
1963 The Linear Ubiquitin Chain Assembly Complex Acts as a Liver Tumor Suppressor and Inhibits Hepatocyte Apoptosis and Hepatitis
1979 *Radiofrequency Ablation of Hepatocellular Carcinoma as Bridge Therapy to Liver Transplantation: A 10-Year Intention-to-Treat Analysis
Min Woo Lee, Steven S. Raman,
Nazanin H. Asvadi, Surachate Siripongsakun, Robert M. Hicks, Jeffrey Chen,
Akeanong Worakitsitisatorn, Justin McWilliams, Myron J. Tong, Richard S. Finn,
Vatche G. Agopian, Ronald W. Busuttil, and David S.K. Lu
A UT O I M M U N E , C H O L E S T A T I C A N D B I L I A R Y D I S E A S E
1991 Bile Duct Ligation–Induced Biliary
Hyperplasia, Hepatic Injury, and Fibrosis Are Reduced in Mast Cell–Deficient KitW-sh Mice
Laura Hargrove, Lindsey Kennedy,
Jennifer Demieville, Hannah Jones, Fanyin Meng, Sharon DeMorrow, Walker Karstens,
Taronish Madeka, John Greene Jr., and Heather Francis
2005 The Role of Sphingosine 1-Phosphate Receptor 2 in Bile-Acid–Induced
Cholangiocyte Proliferation and Cholestasis-Induced Liver Injury in Mice
Yongqing Wang, Hiroaki Aoki, Jing Yang, Kesong Peng, Runping Liu, Xiaojiaoyang Li, Xiaoyan Qiang, Lixin Sun, Emily C. Gurley, Guanhua Lai, Luyong Zhang, Guang Liang, Masayuki Nagahashi, Kazuaki Takabe, William M. Pandak, Phillip B. Hylemon, and Huiping Zhou
L I V E R F A I L U R E / C I R R H O S I S / P O R T A L H Y P E R T E N S I O N
2019 *Left Ventricular Systolic Function Is
Associated With Sympathetic Nervous Activity and Markers of Inflammation in Cirrhosis
Raquel Yotti, Cristina Ripoll, Yolanda Benito, Maria Vega Catalina, Jaime Elızaga, Diego Rincon, Francisco Fernandez-Aviles, Javier Bermejo, and Rafael Ba~nares
(See Editorial on Page 1799)
2031 The Anticoagulant Rivaroxaban Lowers Portal Hypertension in Cirrhotic Rats Mainly by Deactivating Hepatic Stellate Cells
Marina Vilaseca, Hector Garcıa-Caldero, Erica Lafoz, Oihane Garcıa-Irigoyen, Matıas A. Avila, Joan Carles Reverter, Jaume Bosch, Virginia Hernandez-Gea, Jordi Gracia-Sancho,
and Joan Carles Garcıa-Pagan
2045 Ammonia Lowering Reverses Sarcopenia of Cirrhosis by Restoring Skeletal
Muscle Proteostasis
Avinash Kumar, Gangarao Davuluri, Rafaella Nascimento e Silva,
Marielle P.K.J. Engelen, Gabrie A.M. Ten Have, Richard Prayson, Nicolaas E.P. Deutz, and Srinivasan Dasarathy
L I V E R I N J U R Y / R E G E N E R A T I O N
2059 Toll-Like Receptor 5 Signaling Restrains T-Cell/Natural Killer T-Cell Activation and Protects Against Concanavalin A–Induced Hepatic Injury
Lei Wang, Wen Zhang, Chang-Hui Ge, Rong-Hua Yin, Yang Xiao, Yi-Qun Zhan, Miao Yu, Chang-Yan Li, Zhi-Qiang Ge, and Xiao-Ming Yang
L I V E R B I O L O G Y / P A T H O B I O L O G Y
2074 *Activation of Silent Mating Type Information Regulation 2 Homolog 1 by Human Chorionic Gonadotropin Exerts a Therapeutic Effect on Hepatic Injury and Inflammation
Caroline Steinmetz, Anubha Kashyap,
Reviews
2090 Is Moderate Alcohol Use in Nonalcoholic Fatty Liver Disease Good or Bad? A Critical Review
Veeral H. Ajmera, Norah A. Terrault, and Stephen A. Harrison
2100 Nonalcoholic Fatty Liver Disease in Adolescents and Young Adults: The Next Frontier in the Epidemic
Iliana Doycheva, Kymberly D. Watt, and Naim Alkhouri
Hepatology Elsewhere
2110 Synchrony Between Suprachiasmatic Nucleus-Driven Signals and the Light/Dark Cycle Is Essential for Liver Homeostasis
Ruud M. Buijs and Natali Guerrero Vargas
Clinical Observations in
Hepatology
2113 *Emerging Secondary Syphilis Presenting as Syphilitic Hepatitis
Alberto Rubio-Tapia, Isabel A. Hujoel, Thomas C. Smyrk, and John J. Poterucha
2116 *Favorable Short-Term Outcome of Hepatitis C Virus–Positive Liver Graft With Bridging Fibrosis: A Plea for Very Early Viral Eradication
Silvia Martini, Mauro Salizzoni, Ezio David, Francesco Tandoi, Paolo Fonio, Luisa Delsedime, Silvia Strona, Dominic Dell Olio,
Giorgio Maria Saracco, and Renato Romagnoli
Correspondence
2119 Dysmetabolic Iron Overload Syndrome: The Need for an Accurate Liver Iron
Concentration Determination by Magnetic Resonance Imaging
Agustin Castiella, Jose M. Alustiza, Eva Zapata, Leire Zubiaurre, Pedro Otazua,
and Jose I. Emparanza
2119 Reply
Fabrice Laine, Edouard Bardou-Jacquet, Anita Paisant, Yves Gandon, and Yves Deugnier
2120 Comment on ‘‘Esophageal Balloon Tamponade vs. Esophageal Stent in Controlling Acute Refractory Variceal Bleeding: A Multicenter RCT’’
Felix Gundling, Maximilian Tiller, and Wolfgang Schepp
2121 Reply
Angels Escorsell, Oana Pavel, Andres Cardenas, Rosa Morillas, Elba Llop, Candid Villanueva, Juan Carlos Garcia-Pagan, and Jaime Bosch
2122 NAFLD, Hepatotropic Viruses, and Cardiometabolic Risk
Amedeo Lonardo, Fabio Nascimbeni, and Stefano Ballestri
2123 Reply
Eun-Jeong Joo, Yoosoo Chang, and Seungho Ryu
2124 Race or Genetic Makeup for Hepatitis C Virus Treatment Decisions?
Thomas R. O’Brien, Shyam Kottilil, Jordan J. Feld, Timothy R. Morgan, and Ruth M. Pfeiffer
2125 Reply
Feng Su and George N. Ioannou
2126 Do We Need Controlled Attenuation
Parameter Adjustment for Fibrosis Estimation in Nonalcoholic Fatty Liver Disease Patients?
Thomas Karlas, Sebastian Beer, Jonas Babel, Harald Busse, Alexander Schaudinn, Nicolas Linder, Johannes Wiegand, and David Petroff
2128 Reply
Salvatore Petta, Vincent Way-Sun Wong, and Victor de Ledinghen
2129 Addressing Opioid Use Disorder in Modeling Hepatitis C Transmission Among Persons Who Inject Drugs
Jacob Meacham Smith and Josiah D. Rich
2129 Reply
Anthony Cousien, Viet Chi Tran,
Sylvie Deuffic-Burban, Marie Jauffret-Roustide, Jean-Stephane Dhersin, and Yazdan Yazdanpanah
2131 Noninvasive Assessment of Varices Needing Treatment in Patients With Advanced Chronic Liver Disease: No One Should Be Left Behind
2131 Reply
Juan G. Abraldes and Annalisa Berzigotti, on behalf of the ANTICIPATE INVESTIGATORS
2132 MR Lymphography of Hepatic Lymphatic System
Lionel Arrive and Sana^a El Mouhadi
2134 Reply
Yasuko Iwakiri
2135 Corrections
Obituary
2137 Juan Rodes, M.D., Ph.D. (1938–2017): Excellence and Leadership